Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?

Peter R Carroll; Andrew J Vickers

doi:10.6004/jnccn.2014.0186

Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?

J Natl Compr Canc Netw. 2014 May;12(5 Suppl):768-71. doi: 10.6004/jnccn.2014.0186.

Authors

Peter R Carroll¹, Andrew J Vickers¹

Affiliation

¹ Presented by Peter R. Carroll, MD, MPH, Professor and Chair, Department of Urology, University of California, San Francisco, San Francisco, California, and Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City, and Professor of Medicine, Weill Medical College of Cornell University, New York City, New York.

PMID: 24853213
DOI: 10.6004/jnccn.2014.0186

Abstract

Few clinical issues have polarized the oncology community as much as screening for prostate cancer, with advocates of prostate-specific antigen (PSA) testing vocal on one side and skeptics just as vocal on the other. At the NCCN 19th Annual Conference, Dr. Peter R. Carroll and Dr. Andrew J. Vickers tackled the controversy surrounding early detection of prostate cancer, focusing attention on the randomized trial results at the heart of the matter; over-detection (the Achilles' heel of screening); and the rationale behind the new, streamlined 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection, which emphasize selective early detection and treatment and are tightly aligned with the NCCN Guidelines for Prostate Cancer.

Publication types

Editorial
Review

MeSH terms

Biomarkers, Tumor / metabolism
Early Detection of Cancer*
Humans
Male
Practice Guidelines as Topic
Prostate-Specific Antigen / metabolism
Prostatic Neoplasms / diagnosis*
Randomized Controlled Trials as Topic

Substances

Biomarkers, Tumor
Prostate-Specific Antigen

Grants and funding

P50 CA092629/CA/NCI NIH HHS/United States